PI3K GENE MUTATION
Clinical trials for PI3K GENE MUTATION explained in plain language.
Never miss a new study
Get alerted when new PI3K GENE MUTATION trials appear
Sign up with your email to follow new studies for PI3K GENE MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare blood vessel disorders: targeted drugs enter trial
Disease control Recruiting nowThis study tests two targeted drugs for people with abnormal blood vessels (vascular malformations). One drug, alpelisib, is for slow-flow types; the other, mirdametinib, is for fast-flow types. About 50 participants aged 2 and older will take the drug for 48 weeks to see if thei…
Matched conditions: PI3K GENE MUTATION
Phase: PHASE2 • Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
New precision drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug, OKI-219, designed to block a specific cancer-driving mutation (PI3KαH1047R) found in some advanced solid tumors and breast cancers. About 200 adults whose cancer has this mutation will receive OKI-219 alone or combined with other anti-canc…
Matched conditions: PI3K GENE MUTATION
Phase: PHASE1 • Sponsor: OnKure, Inc. • Aim: Disease control
Last updated May 11, 2026 20:38 UTC